BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Penpulimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Penpulimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04344158-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Penpulimab: Phase 3 readout est. (NCT04344158)
DESCRIPTION:Penpulimab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Phas
 e III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochlor
 ide Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Car
 cinoma (HCC)\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/penpulimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04344158
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081673-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Penpulimab: Phase 2 readout est. (NCT06081673)
DESCRIPTION:Penpulimab\, phase 2.\nStudy: Penpulimab Combined With Chemothe
 rapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSC
 C\nEstimated primary completion: 30 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/penpulimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06081673
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075419-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Penpulimab: Phase 1/2 readout est. (NCT07075419)
DESCRIPTION:Penpulimab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: JDB1
 53 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Tr
 eatment Failure\nEstimated primary completion: 1 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/penpulimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07075419
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821503-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Penpulimab: Phase 1/2 readout est. (NCT06821503)
DESCRIPTION:Penpulimab\, phase 1/2.\nStudy: Clinical Study Evaluating the S
 afety\, Tolerability\, and Preliminary Efficacy of LM-108 ± Penpulimab+Ch
 emotherapy in Advanced Solid Tumors - Cohort C\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 npulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06821503
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764601-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Penpulimab: Phase na readout est. (NCT07764601)
DESCRIPTION:Penpulimab\, phase na.\nStudy: R-MA-PD-1 Versus R-MA in Treatme
 nt-naive Primary CNS Lymphoma\nEstimated primary completion: August 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/penpulimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07764601
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Penpulimab: Phase 2 readout est. (NCT06516978)
DESCRIPTION:Penpulimab\, phase 2.\nStudy: A Study Comparing the Efficacy an
 d Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreat
 ed Patients With DLBCL\nEstimated primary completion: 1 October 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/penpulimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06516978
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904130-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Penpulimab: Phase 2 readout est. (NCT07904130)
DESCRIPTION:Penpulimab\, phase 2.\nStudy: Personalized Ultrafractionated St
 ereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib
  for Advanced Colorectal Cancer\nEstimated primary completion: 1 October 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/penpulimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07904130
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381075-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Penpulimab: Phase 2 readout est. (NCT07381075)
DESCRIPTION:Penpulimab\, phase 2.\nStudy: A Phase II Clinical Trial of Anti
 -EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkp
 oint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advance
 d Head and Neck Squamous Cell Carcinoma\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/penpul
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07381075
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612098-1993@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Penpulimab: Phase 2 readout est. (NCT07612098)
DESCRIPTION:Penpulimab\, phase 2.\nStudy: Preoperative Radiotherapy and Anl
 otinib With or Without Penpulimab for Soft Tissue Sarcoma\nEstimated prima
 ry completion: 31 December 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/penpulimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07612098
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
